Horizon will acquire Raptor for $9 per share in cash, or $800 million. The deal strengthens the company’s orphan business and should accelerate growth outside of the U.S. in 2017 and beyond.

Horizon Pharma (HZNP) announced its intention of acquiring rare-disease focused biotech company Raptor Pharmaceuticals (RPTP) in a deal worth about $800 million.

Horizon Pharma (HZNP) announced on Monday that it is acquiring fellow drugmaker Raptor Pharmaceutical (RPTP) for $800 million. The deal, due to close in the fourth quarter, is set to bump up ...

If we look at what Horizon is paying, it doesn’t necessarily add up, ... Raptor’s previously disclosed total net sales guidance for full-year 2016 is $125 million to $135 million, ...

The robot, appropriately named Raptor, is bipedal like its namesake. It features two flexible feet, made out of a carbon-fiber/epoxy composite, which are attached to lightweight legs.

Horizon Pharma Plc said it would buy Raptor Pharmaceutical Corp for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market.

Horizon was down 1.5% premarket on the news this morning, while Raptor was up 20% premarket to $7.45 a share. mergers and acquisitions Horizon Pharma Ireland Raptor Pharmaceutical Clinical Data ...

Of course, that record was also beaten in December of 2023 by another four-legged robot from KAIST – the same place that developed the Raptor – called Hound, when it ran the 100-meter dash in ...